KRAS and colon carcinoma: Indeed, the presence of KRAS-mutated CTCs in patients with KRAS wild-type primary colon carcinomas might be one explanation for failure of drug-mediated EGFR inhibition in these patients (Douillard et al, 2013; Peeters et al, 2013).